Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

(2009) Dirk Nagorsen et al.   LEUKEMIA & LYMPHOMA

Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression

(2008) Patrice Chevallier et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

(2008) P Chevallier et al.   LEUKEMIA

Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg

(2008) Ka-Chun Cheung et al.   LEUKEMIA & LYMPHOMA

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells

(2008) Sandrine d’Argouges et al.   LEUKEMIA RESEARCH

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE